BioCentury
ARTICLE | Company News

Raptor acquires Quinsair

August 22, 2015 2:01 AM UTC

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) acquired aerosolized levofloxacin ( MP-376) from Tripex Pharmaceuticals LLC, a privately held shell company. The formulation, which Raptor intends to market as Quinsair, is approved in the EU and Canada to manage chronic Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF).

Raptor will pay $68.4 million up front for the candidate and has the option to pay half in stock. Tripex is eligible for $350 million in milestone payments and single-digit royalties. Raptor spokesperson Cammy Duong said the company will also pay single-digit royalties to Allergan plc (NYSE:AGN) and Pari GmbH (Starnberg, Germany); both companies were involved in Quinsair's development. The product uses the eFlow Nebulizer System from Pari. ...